Galcanezumab (Emgality) (Galcanezumab-gnlm) for Personal Injury

Drug Class: CGRP Ligand Monoclonal Antibody — Preventive (Monthly Injection)

Common Uses

  • Preventive treatment of episodic migraine
  • Preventive treatment of chronic migraine
  • Prevention of episodic cluster headache (unique indication in this class)
  • Post-traumatic migraine following car accidents, whiplash, or TBI

How It Helps in Personal Injury Cases

Galcanezumab (Emgality) is the only CGRP monoclonal antibody with FDA approval for cluster headache prevention — a condition that can be triggered or worsened by head trauma. In personal injury cases, cluster headaches following head impact represent a distinct and particularly severe neurological consequence. For migraine, the loading dose in the first month (240mg — two 120mg injections) creates strong documentation of aggressive treatment initiation.

Galcanezumab targets the CGRP ligand itself (rather than its receptor), binding to circulating CGRP and neutralizing it before it can bind to receptors and trigger migraine. Monthly injection maintains sustained CGRP neutralization between doses. The loading dose approach — double the maintenance dose in the first month — provides rapid onset of preventive coverage important for patients with high migraine burden.

Galcanezumab (Emgality) for Post-Traumatic Migraine and Cluster Headache

Galcanezumab, sold as Emgality, is a monthly injectable CGRP monoclonal antibody for migraine prevention and the only FDA-approved treatment for episodic cluster headache.

Unique Dual Indication

Most CGRP antibodies are approved only for migraine. Emgality holds the additional FDA indication for episodic cluster headache prevention — a condition characterized by severe, unilateral headache attacks in cyclical patterns. Head trauma can trigger cluster headache patterns in susceptible patients, making this indication particularly relevant for PI cases involving significant head impact.

Loading Dose Protocol

Unlike the other injectable CGRP antibodies, Emgality uses a loading dose in the first month:

  • Month 1: 240mg (two 120mg injections administered together)
  • Months 2+: 120mg monthly maintenance

The loading dose establishes therapeutic drug levels rapidly, providing faster onset of preventive coverage.

Clinical Evidence

The EVOLVE trials (episodic migraine) demonstrated approximately 4.7 fewer migraine days per month versus placebo. The REGAIN trial (chronic migraine) demonstrated approximately 4.3 fewer headache days per month. For cluster headache, the CONQUER trial showed Emgality significantly reduced cluster attack frequency.

Documentation Value in PI Cases

The loading dose creates a particularly strong initial documentation event — two injections in the first month signal a treating neurologist's determination that aggressive, immediate preventive coverage was clinically warranted.

Accessing Galcanezumab Through LienScripts

Galcanezumab (Emgality) is brand-name only. LienScripts provides pharmacy lien coverage at $0 upfront cost for qualified personal injury patients.

Dosage Forms

  • Autoinjector pen 120mg/mL — monthly maintenance
  • 240mg loading dose (two 120mg injections) in first month, then 120mg monthly
  • Cluster headache dosing: 300mg monthly (three 100mg injections)

Common Side Effects

  • Injection site reactions (most common)
  • Constipation
  • Allergic reactions (rare)
  • Fatigue (uncommon)

Frequently Asked Questions

What is the loading dose and why does it matter?

Galcanezumab uses a 240mg loading dose in the first month — twice the monthly maintenance dose. This front-loading rapidly establishes therapeutic drug levels, providing faster onset of migraine prevention. The loading dose is clinically significant because it documents the treating neurologist's intent to establish rapid preventive coverage.

Can Emgality treat cluster headaches from a head injury?

Yes. Galcanezumab (Emgality) is the only FDA-approved pharmacological treatment specifically for episodic cluster headache. Head trauma can trigger or worsen cluster headache patterns, and Emgality is the appropriate first-in-class treatment when this occurs after a personal injury.

How is Emgality different from Aimovig?

Both are monthly injectable CGRP antibodies, but they have different molecular targets. Aimovig (erenumab) blocks the CGRP receptor; Emgality (galcanezumab) neutralizes the CGRP ligand itself. Emgality also has the unique cluster headache indication and uses a loading dose in the first month.

Is there a biosimilar for Emgality?

No. Galcanezumab is available only as Emgality with no biosimilar alternatives currently approved in the United States.